Germany’s medical cannabis market, which has long been the engine powering Europe’s wider market growth, once again finds itself in a state of flux.
Following more than a year of reliable quarterly growth, the latest BfArM import figures point to a decline in the first three months of 2026. While it’s not yet clear whether this decline is due to reporting delays that will be rectified when Q2 data is published, it is just the tip of the iceberg in a market facing several potential shifts.
The staunchly anti-CanG CDU, which became the country’s largest ruling coalition party in early 2025 having promised to reverse the previous government’s cannabis act in its manifesto, is now showing signs of softening on cannabis in light of its undeniable popularity.
Beyond politics, Germany continues to attract major international investment, often through M&A deals, seeing brands and products continue to pour into the market, piling pressure on margins.
With regulatory, commercial, and political pressures pulling simultaneously in different directions, having an accurate picture of the market’s actual size and value has become a baseline requirement for any operator, investor, or analyst with exposure to Germany.
In preparation for tomorrow’s European Cannabis Insights Summit 2026, taking place in Berlin on June 10th, Prohibition Partners has prepared a comprehensive new data pack on the German market, which will be exclusively available to delegates.
The German Medical Cannabis Data Package covers market sizing, product pricing, wholesale data, and includes a dedicated Patient Patterns chapter to be delivered post-event. The data is now available to purchase with a ticket to the summit.
Events European Cannabis Insights Summit 2026 200+ business leaders from the global cannabis industry come together to discuss the future of trade, innovations and policy in Europe's most important emerging market.
secure your place & data pack now →
Estimates built on import volumes alone no longer capture the full picture, and in a market where a single legislative outcome could move annual revenues by hundreds of millions of euros, the margin for error is narrowing.
Key to understanding the market beyond the public import data is determining how much of that product actually makes it into the hands of patients.
Prohibition Partners estimates that up to 40% of imported flower is never dispensed, with the remainder accounted for by inventory build, product expiry, specification failures, and re-export.
By modelling the market across a range of scenarios, varying the share of total supply that ultimately reaches patients, Prohibition Partners estimates that the overall value of the sector could differ by more than €300m this year alone.
Delving into the products that are consistently reaching patients, the data shows that between the start of 2025 and mid-2026, the number of tracked flower lines has risen from 724 to over 1,800.
In turn, this has had a significant impact on price, seeing the average price per gram fall by nearly a third. While a premium tier of flower priced above €9 has survived the price crunch, scale and supply chain efficiency are becoming increasingly vital for operators to edge ahead of competitors.
Current market leaders, according to Prohibition Partners, include the recently acquired Remexian Pharma, Enua Pharma, Cantourage, Demecan, and Cannamedical.
Despite a number of these operators holding domestic cultivation licences, German-grown flower remains a niche category. Domestic production in 2025 is estimated at approximately 2.4 tonnes against more than 200 tonnes imported, and is not expected to represent a meaningful share of supply by 2030.
The questions that will define Germany’s cannabis market through the remainder of the decade, how far the MedCanG amendment goes, whether the SHI reimbursement channel survives, and whether the CDU’s softening on Pillar 2 represents a genuine shift, are precisely those on the agenda in Berlin.
For operators making supply, investment, and market-entry decisions in that environment, the Prohibition Partners data pack represents the most current commercial baseline available. Secure your place and access the full dataset here.
The post Public Data is No Longer Enough to Understand the German Medical Cannabis Market appeared first on Business of Cannabis.
Continue reading...
Following more than a year of reliable quarterly growth, the latest BfArM import figures point to a decline in the first three months of 2026. While it’s not yet clear whether this decline is due to reporting delays that will be rectified when Q2 data is published, it is just the tip of the iceberg in a market facing several potential shifts.
The staunchly anti-CanG CDU, which became the country’s largest ruling coalition party in early 2025 having promised to reverse the previous government’s cannabis act in its manifesto, is now showing signs of softening on cannabis in light of its undeniable popularity.
Beyond politics, Germany continues to attract major international investment, often through M&A deals, seeing brands and products continue to pour into the market, piling pressure on margins.
With regulatory, commercial, and political pressures pulling simultaneously in different directions, having an accurate picture of the market’s actual size and value has become a baseline requirement for any operator, investor, or analyst with exposure to Germany.
In preparation for tomorrow’s European Cannabis Insights Summit 2026, taking place in Berlin on June 10th, Prohibition Partners has prepared a comprehensive new data pack on the German market, which will be exclusively available to delegates.
The German Medical Cannabis Data Package covers market sizing, product pricing, wholesale data, and includes a dedicated Patient Patterns chapter to be delivered post-event. The data is now available to purchase with a ticket to the summit.
Events European Cannabis Insights Summit 2026 200+ business leaders from the global cannabis industry come together to discuss the future of trade, innovations and policy in Europe's most important emerging market.
secure your place & data pack now →
Germany Medical Cannabis Data Package, key insights
Estimates built on import volumes alone no longer capture the full picture, and in a market where a single legislative outcome could move annual revenues by hundreds of millions of euros, the margin for error is narrowing.
Key to understanding the market beyond the public import data is determining how much of that product actually makes it into the hands of patients.
Prohibition Partners estimates that up to 40% of imported flower is never dispensed, with the remainder accounted for by inventory build, product expiry, specification failures, and re-export.
By modelling the market across a range of scenarios, varying the share of total supply that ultimately reaches patients, Prohibition Partners estimates that the overall value of the sector could differ by more than €300m this year alone.
Delving into the products that are consistently reaching patients, the data shows that between the start of 2025 and mid-2026, the number of tracked flower lines has risen from 724 to over 1,800.
In turn, this has had a significant impact on price, seeing the average price per gram fall by nearly a third. While a premium tier of flower priced above €9 has survived the price crunch, scale and supply chain efficiency are becoming increasingly vital for operators to edge ahead of competitors.
Current market leaders, according to Prohibition Partners, include the recently acquired Remexian Pharma, Enua Pharma, Cantourage, Demecan, and Cannamedical.
Despite a number of these operators holding domestic cultivation licences, German-grown flower remains a niche category. Domestic production in 2025 is estimated at approximately 2.4 tonnes against more than 200 tonnes imported, and is not expected to represent a meaningful share of supply by 2030.
The questions that will define Germany’s cannabis market through the remainder of the decade, how far the MedCanG amendment goes, whether the SHI reimbursement channel survives, and whether the CDU’s softening on Pillar 2 represents a genuine shift, are precisely those on the agenda in Berlin.
For operators making supply, investment, and market-entry decisions in that environment, the Prohibition Partners data pack represents the most current commercial baseline available. Secure your place and access the full dataset here.
The post Public Data is No Longer Enough to Understand the German Medical Cannabis Market appeared first on Business of Cannabis.
Continue reading...
